Good morning :)
$
₹
QuidelOrtho Corp

QuidelOrtho Corp

QDEL

NASDAQ
Asset Logo

QuidelOrtho Corp

QDEL

NASDAQ
$14.351.85% (+0.26)
$
₹
$14.351.85% (+0.26)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Small Cap

With a market cap of $962.1M the stock is ranked 2752

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.51
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-15.39
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

2.06
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-39.2%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
1 analyst
Hold
1 analyst
Sell
1 analyst

Price Upside

+2.21%

Earnings Growth

-63.52%

Rev. Growth

-6.82%

See Detailed Forecast

Company Profile

Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Medline Inc. Class A Common Stock
MDLN
M
P/E Ratio
80.07
80.07
1Y Return
1.58%
1.58%
Buy Reco %
85.18
85.18
West Pharmaceutical Services Inc
WST
West Pharmaceutical Services Inc
P/E Ratio
45.77
45.77
1Y Return
42.57%
42.57%
Buy Reco %
93.75
93.75
The Cooper Companies, Inc
COO
The Cooper Companies, Inc
P/E Ratio
21.06
21.06
1Y Return
11.94%
11.94%
Buy Reco %
35.29
35.29
Align Technology Inc
ALGN
Align Technology Inc
P/E Ratio
22.46
22.46
1Y Return
11.72%
11.72%
Buy Reco %
50.00
50.00
Bausch + Lomb Corp
BLCO
Bausch + Lomb Corp
P/E Ratio
—
—
1Y Return
33.53%
33.53%
Buy Reco %
46.66
46.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 2.21% growth, versus a trailing 3-year CAGR of -38.88%.

2026
Current$14.35Baseline
Analyst Target - 1 year
Target$14.67+2.21%

All values in $

202220232024202520262027$33.25$53.58$73.91Target+2.21%
2026
Current$14.35Baseline
Analyst Target - 1 year
Target$14.67+2.21%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -6.82% growth, versus a trailing 3-year CAGR of -5.80%.

2025
Current$2.73Baseline
Forecast for Dec 2026
High$2.55-6.34%
Average$2.54-6.82%
Low$2.51-7.72%

All values in $ Billion

2021202220232024202520261.693.262.992.782.73Low-7.72%Average-6.82%High-6.34%
2025
Current$2.73Baseline
Forecast for Dec 2026
High$2.55-6.34%
Average$2.54-6.82%
Low$2.51-7.72%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -63.52% growth, versus a trailing 3-year CAGR of -50.62%.

2025
Current$2.12Baseline
Forecast for Dec 2026
High$0.8-62.26%
Average$0.77-63.52%
Low$0.75-64.78%

All values in $

20212022202320242025202617.7817.614.131.852.12Low-64.78%Average-63.52%High-62.26%
2025
Current$2.12Baseline
Forecast for Dec 2026
High$0.8-62.26%
Average$0.77-63.52%
Low$0.75-64.78%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

699.9
-733
723.6
-130.7
619.8
-91.8
630.9
-92.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.710.630.720.700.690.610.690.720.610.63
Net Income-1.70-0.14-0.01-0.17-0.01-0.25-0.73-0.13-0.09-0.09
Net Profit Margin-239.94%-23.18%-2.73%-25.20%-1.83%-41.60%-104.72%-18.06%-14.81%-14.72%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
QuidelOrtho Corp -0.512.06
Medline Inc. Class A Common Stock80.072.43-
West Pharmaceutical Services Inc45.779.683.21
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare QDEL with any stock or ETF
Compare QDEL with any stock or ETF
Comparing from
QDEL
MDLN
WST
Loading...

Frequently asked questions

  1. QuidelOrtho Corp (QDEL) share price today is $14.35 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $14.64 and a day low of $13.72.

  2. QuidelOrtho Corp stock trades on NASDAQ under the ticker symbol QDEL.

  3. QuidelOrtho Corp's market capitalization is $962.11M as of November 5, 2026 at 2:29 AM IST.

  4. QuidelOrtho Corp's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. QuidelOrtho Corp's price-to-book (P/B) ratio is 0.51 as of November 4, 2026.

  6. Yes, You can buy QuidelOrtho Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy QuidelOrtho Corp shares in three steps: 1. Search QuidelOrtho Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since QuidelOrtho Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in QuidelOrtho Corp (QDEL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.6968 shares at the current price of $14.35.

Loading...